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Transplantation of HLA-matched bone marrow after total body irradiation in man is
frequently followed by graft-versus-host disease (GVHD)t (1). The pathogenesis of this syn-
drome is controversial. Certainworkers maintain that the disease, particularly its chronic form
(secondary disease), reflects an attack against minor histocompatibility (H) antigens of the host
by the progeny of stem cells in the marrow inoculum (1, 2). Although widely held, this
viewpoint is difficult to reconcilewith the following observations. First, irradiated Ft mice given
parental strain fetal liver cells (3, 4) or T-cell-depleted marrow cells (5) fail to develop GVHD
even across major histocompatibility complex (MHC) barriers. Second, GVHD is not seen in
embryo-fusion chimeras (6) or in natural hemopoietic chimeras (7-9). Production of blocking
factors, etc. have to be invoked to explain these findings.
Theopposing viewpoint is that the GVHD seen with HLA-matched marrow does not reflect
alloaggression mediated by stem cells or their progenybut by mature T cells contaminating the
marrow inoculum (5). The main objectionto this notion is that, although T cells are known to
control GVH reactions against MHC determinants, ". . . there is no evidence whatsoever that
removal of the cells that produce GVH reactions influences the occurrence of the delayed type
of GVH disease that is associated with weak incompatibilities" (10) . The mouse is theobvious
choice for examining this question since reagents with defined specificity for mature Tcells are
available only in this species. Surprisingly, although secondary disease to non-MHC determi-
nants is well-documented in dogs (11), there are only isolated reports that transfer of MHC-
identical marrow causes lethal GVHD in heavily irradiated mice (12) . In certain situations
spleen and lymph node cells cause heavy mortality in H-2-compatible mice given lethal
irradiation (13), or sublethal irradiation plus cylophosphamide (14) ; mortality was not seen in
a recent study employing sublethal irradiation alone (15) . In terms of splenomegaly and
mortality assays in neonatal mice, it is well-accepted that minor H differences cause minimal
reactionsunless the donors are presensitized (16, 17). Similarly, cytotoxic reactions to minor H
antigens are very weak except in secondary responses (18) .
It is critical to distinguish between the above twotheories for thecause of secondary disease.
Thus, the first viewpoint is essentially pessimistic since it implies that with sufficient antigenic
disparity between donor and host, GVHD is inevitable and amenable only to palliative
treatment, e.g. immunosuppression. By contrast, the second viewpoint asserts that GVHD will
not occur if the marrow inoculum is depleted of mature T cells.
In attempting to resolve this controversy theaim ofthe present paper was to studytheeffects
of bone marrow transplantation across minor H barriers in mice. The data show that, at least
with certain strain combinations, untreated marrow cells caused a high incidence of lethal
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chronic GVHD when transferred to heavily irradiated allogeneic recipients. Significantly,
GVHD did not occur when the marrow cells were depleted of mature T cells with anti-Thy 1 .2
antiserum and complement.
Materials and Methods
Mice.
￿
CBA/J, BlO.BR/SgSn, C3H/HeJ, CBA/H-T6J, and AKR/J (all H-2k ) and C57BL/
6J (B6), C57BL/IOJ (B10) and 129/J (all H-28 ) were obtained from The Jackson Laboratory,
Bar Harbor, Maine. B IO.K (H-2k ) mice were a gift from W. L. Elkins, University of
Pennsylvania. (B6 X CBA/J)Fl mice were purchased from Cumberland View Farms, Clinton,
Tenn. (BIO X B10.BR)Fl and (C3H/He X BALB/c (H-2d ))Fi mice were bred in our colony.
Unless stated otherwise, male mice were used as donors and recipients. Mice 2-4 mo old were
used as irradiated recipients of marrow cells after being maintained on a conventional diet and
acid water ad libitum.
Media.
￿
RPMI-1640 (Microbiological Associates, Walkersville, Md.) supplemented with 10%
fetal calf serum was used.
Injections.
￿
Cell suspensions were given intravenously in 0.5 ml via the tail vein.
Viability.
￿
Cell viability was assessed by dye exclusion.
Cells.
￿
Bone marrow cells were obtained from tibia and femura by gentle flushing with cold
medium via a 25 gauge needle. Clumps were removed by passage over sterile cotton filters and
the cells were washed three times by centrifugation before final resuspension. Spleen and lymph
node (LN) cells were obtained by mincing the organs with curved scissors over an 80-mesh
stainless steel sieve in cold medium. T-cell-enriched populations of LN cells were obtained by
passage through nylon wool columns as described by Julius et al. (19) . Over 90% of the effluent
cells were T cells as tested by their susceptibility to lysis by anti-Thy 1 .2 antiserum in the
presence of guinea pig complement.
Removal ofMature T Cells from Bone Marrow.
￿
After centrifugation, marrow suspensions were
resuspended in a 1 :5 dilution of anti-Thy 1.2 serum (0.1 ml undiluted serum/5 X 107 cells) and
incubated on ice for 30 min. The cells were then washed twice with at least 20 ml of medium
and suspended in a 1:6 dilution of guinea pig complement (1 .0 ml undiluted complement/3
X 108 cells) . After a final incubation in a 37°C water bath for 30 min with occasional mixing,
the cells were washed three times with medium and resuspended to the required concentration.
Control experiments showed that this procedure lysed >98% of highly purified T cells, i.e. LN
cells recirculated from blood to lymph through irradiated intermediate hosts (20).
LN cells were depleted of T cells by the same two-step procedure except that a higher
concentration of anti-Thy 1 .2 serum was used (0.1 ml of undiluted serum/2 X 107 cells) .
Antisera.
￿
Anti-Thy 1 .2 antiserum was made by injecting AKR/J mice with 2 X 107 C3H/
HeJ thymus cells intraperitoneally at weekly intervals for 12 wk. CBA anti-B6 H-2 alloantiserum
was made as described elsewhere (20).
Mortality Assay for GVHD.
￿
Marrow recipients were given 750 rads of 137CS y-irradiation at
a dose rate of 106 rads/min. Groups of mice were split into separate cages and kept in a laminar
flow room. Neomycin (50 Ntg/1) and Polymyxin B (50 Ftg/ml) were added to the drinking water
for 3 wk after irradiation.
Plaque-Forming Cell (PFC) Assays. IgM (direct), IgG (indirect), and Ig
b-allotype PFC to
sheep erythrocytes (SRC) were assayed as described elsewhere (21). IgG PFC were developed
with a polyvalent rabbit anti-mouse Ig antiserum; Igb PFC were developed with a BALB/c
anti-B6 Ig (anti-Igb) anti-allotype serum (21).
Results
Experimental Design.
￿
In all experiments mice received a lethal dose of irradiation
(750 rads). 6-8 h later the mice were injected intravenously with 107 marrow cells
alone or with the same dose of marrow cells mixed with other cell types. Unless stated
otherwise, neither the donors nor the hosts were presensitized. The cell recipients were
weighed thrice weekly and examined for signs of GVHD for 80 days or until death.
Antibiotics (see Materials and Methods) were added to the drinking water for theloo --r
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Lethal GVHD in irradiated (750 rads) CBA/J mice given unfractionated BlO.BR marrow
cells. The data show cumulative mortality after injection of untreated syngeneic CBA/J marrow
cells (CBA BM), B10.BR marrow cells treated with anti-Thy 1.2 serum and complement (B10.BR
aB BM), or with B10.BR marrow cells treated with normal AKR serum and complement (B10.BR
N BM) . 107 viable marrow cells injected intravenously. Data pooled from three separate experiments
involving a total of 30 mice per group.
first 3 wk postirradiation. Greater than 80% of irradiated mice not protected with
marrow cells died of hemopoietic failure within 3 wk.
Transfer of BIO.BR Marrow to Irradiated CBA/f Mice.
￿
Fig. 1 illustrates mortality
occurring in irradiated CBA/J (H-2k ) mice reconstituted with syngeneic CBA/J
marrow or with H-2-compatible B lO.BR marrow (B lO.BR and CBA/J express
multiple non-MHC antigen differences (vide infra) ; the data are pooled from three
experiments involving a total of 30 mice per group.) As expected, only low mortality
occurred when syngeneic marrow was injected. Although a few mice died within the
first 3-4 wk, there were no deaths after 30 days.
A very different pattern was observed with B l0.BR marrow cells. Ifthese cells were
not pretreated with anti-Thy 1 .2 antiserum and complement before injection, lethal
chronic GVHD occurred (Fig. 1) . Thus, with transfer of BlO.BR marrow cells treated
with control serum (normal AKR serum) and complement, most of the mice died
after day 30 and only 20% survived beyond day 80. During this stage the mice showed
typical signs of secondary disease before death, e.g. hunched posture, ruffled fur,
weight loss, etc. Skin lesions were not seen.
Significantly, neither morbidity nor mortality occurred when B lO.BR marrow cells
were treated with anti-Thy 1 .2 serum and complement before injection (Fig. 1) . As
with transfer of syngeneic marrow cells, isolated deaths were observed within the 1st
mo but there were no deaths nor signs of ill-health after 30 days.
Potentiation of GVH Disease by Adding T Cells to Marrow Inoculum.
￿
The above data
strongly implied that mature T cells in the marrow inoculum were the cause of
secondary disease. The proportion of T cells in B lO.BR marrow appeared to be very
low since cytotoxic indices with anti-Thy 1.2 serum and complement were <5% (data
not shown). Accordingly, the addition of even small numbers (<5%) of purified T
cells to inocula of anti-Thy 1 .2-serum-treated BlO.BR marrow cellswould be expected
to restore the incidence of secondary disease.
This prediction is verified by the data shown in Fig. 2 in which varying numbers1690
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Lethal GVHD in irradiated (750 rads) CBA/J mice given graded doses of purified Bl0.BR
LN T cells. The data show cumulative mortality after transferring 107 anti-Thy 1 .2-serum-treated
B10.BR marrow cells (B10.BR aO BM) supplemented with varying numbers of nylon-wool-purified
BIO.BR LN T cells or with anti-Thy 1.2 serum-treated BlO.BR LN cells (aO LN). Data pooled from
three experiments involving a total of 18 mice per group.
of nylon-wool purified BlO.BR LN T cells (>90% Thy 1.2-positive) were added to the
dose of 107 T-cell-depleted BlO.BR marrow cells. With the addition of high doses of
T cells (107), all of the recipients died within 21 days, presumably as the result of an
acute GVH reaction. Smaller doses of T cells produced slower mortality, e.g. 100%
mortality was delayed until day 32 with 3 X 106 T cells and until day 42 with 3 X
106 T cells. However, even doses as low as 3 X 104 cells (equivalent to 0.3% T-cell
contamination of the marrow) caused nearly 80% mortality by day 80. It is to be
noted that the addition of high doses of anti-Thy 1.2-serum-treated BlO.BR LN cells
(107 viable cells) caused no mortality.
Inability of Tolerant T Cells to Cause Lethal GVH Disease.
￿
Previous work has shown
that T-cell tolerance to host-type MHC alloantigens occurs when parental strain
marrow cells are transferred to irradiated H-2-different Fl hybrid mice (22) . To
determine whether tolerance to non-H-2 determinants occurs in this situation, lethally
irradiated (900 rads) (B6 (H-2b) X CBA/J)F, mice were reconstituted with 107 anti-
Thy 1.2-serum-treated B10.BR marrow cells. Spleen cells taken from these mice 3 mo
later were >95% of donor B10.BR origin, i.e. were resistant to lysis with CBA/J anti-
B6 H-2 alloantiserum.
As shown in Fig. 3 a high dose of a mixture of 107 marrow cells and 107 pooled
spleen and LN cells from these chimeras failed to cause mortality in irradiated CBA/
J mice. As expected, the chimera cells were reactive to third-party alloantigens, i .e.
they caused rapid mortality in irradiated (C3H/He X BALB/c)F, (H-2k X H-2d)
mice.
GVHD with other H-2-Compatible Combinations.
￿
Results obtained with a variety of
other strain combinations fell into three categories (vide infra) (Table I) .
GVHD with Normal Marrow Cells.
￿
As with transfer of BlO.BR marrow to CBA/J
mice, reciprocal transfer of CBA/J marrow to irradiated BlO.BR mice led to chronic
GVHD. Thus, in the experiment shown in Fig. 4, five of the six marrow recipients
died between day 20 and day 45; the remaining mouse survived for >80 days. No
deaths occurred with syngeneic marrow. Again, T-cell depletion of the allogeneic100
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Failure of specifically tolerant BlO.BR spleen and LN cells to induce lethal GVHD in
irradiated (750 rads) CBA/J mice. B10.BR cells tolerant of CBA/J determinants were obtained
from heavily irradiated (900 rads) (B6 X CBA/J)F, mice reconstituted three months previously
with anti-Thy 1 .2-serum-treated B10.BR marrow cells (see text) . The data show cumulative
mortality in irradiated CBA/J mice given a mixture of 107 marrow cells plus 107 pooled spleen and
LN cells derived from B10.BR --* (B6 X CBA/J)Fi chimeras (group A) or from normal B10.BR
mice (group B). Control experiments involved transferring the same mixture of B10.BR chimera
cells into third-party irradiated (C3H/He X BALB/c)F, mice with or without syngeneic (C3H/He
X BALB/c)F, marrow cells (groups C and D, respectively). Group E mice were irradiated (C3H/
He X BALB/c)Fj mice given syngeneic marrow cells alone. Data pooled from four experiments.
Groups A, B, C, D, and E contained totals of 23, 13, 10, 3, and 8 mice, respectively.
marrow with anti-Thy 1.2 serum prevented both mortality and morbidity and the
addition of normal CBA/J spleen and LN potentiated mortality.
GVHD with Spleen and LN Cells but not with Marrow Alone.
￿
In most strain combina-
tions tested, untreated marrow cells per se did not cause lethal GVHD. However,
with six out of nine of these combinations, marked mortality occurred when the
marrow was supplemented with spleen and LN cells of donor origin. A dose of 10' of
these cells caused 70-100% mortality and 108 cells produced 100% mortality. With
one combination (B10.K -~, CBA/J), studies with nylon-wool-purified LN cells
showed that as few as 3 X 105 purified T cells led to >90% mortality (equivalent to
3% T-cell contamination of the marrow) . It is to be noted that with all of these
combinations there were at least three minor H antigen differences between the donor
and host.
No GVHD.
￿
In the remaining three combinations, the addition of even high doses
(108) of spleen and LN cells caused only a minimal incidence of GVHD (<35%
mortality) . In two of these combinations, only a single minor H antigen difference
was involved, i.e. H-9 for B6 --* B10 and H-Y for B 10 female --> B 10 male (in the
latter situation even presensitized cells were nonlethal [Table I]). In the third
combination, i.e. CBA/H-T6 --+ CBA/J, there were no known minor H differences
present.
Immunocompetence and Extent of Chimerism in Mice given T-Cell-Depleted Allogeneic Mar-
row. Most recipients of anti-Thy 1 .2-serum-treated allogeneic marrow cells were
killed after 3-4 mo for reasons of economy. However, certain groups were kept for
long-term observation and are alive and well after 12 mo. Allogeneic chimeras killed
after 3-4 mo had normal sized spleens and LN. Cell suspensions from pooled1692
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TABLE I
Summary ofMortality Observed after Transferring Untreated Bone Marrow to Lethally Irradiated (750
rails) H-2-Compatible Allogeneic Recipients
Some of the
Deaths by 80 days after transfer of:
￿
GVHD with:
Donor marrow plus Donor
* Drawn from references 23-25 and M. Cherry, personal communication. This list is far from complete; for
example, Ig allotypes and Qa determinants (see footnote 2 in text) are not mentioned.
$ 3 X 105 nylon-wool-purified LN T cells.
§ 3 X 108 nylon-wool-purified LN T cells.
j` Cells taken from donors presensitized with 3 X 107 male spleen and LN cells intravenously 5 wk before.
A prior experiment with unsensitized cells gave no GVHD.
peripheral and mesenteric LN were comparable in cellularity (^-108 cells/mouse) and
proportion of T cells (^-50% Thy 1 .2-positive) to LN suspensions from syngeneic
chimeras.
The experiment illustrated in Table II shows primary anti-SRC responses by
B lO.BR --). CBA/J and CBA/J --* B lO.BR chimeras measured at 4 mo after
reconstitution. Both groups of chimeras gave high IgM and IgG responses which were
Donor
Recipient
(H-2 haplo-
type)
known genetic
differences be-
tween donor and
recipient*
Host
mar-
row
alone
Donor
mar-
row
alone
spleen and LN in
dose of:
10' 108
Donor
mar-
row
alone
mar-
row
plus
spleen
and
LN
BIO.BR CBA/J H-1, -3, -7, -8, -9, 6/40 24/30 18/18 12/12 + +
(H-2k) -12
Tla, Mls, Ly 1, 2
CBA/J B10.BR H-1, -3, -7, -8, -9, 0/6 5/6 6/6 6/6 + +
(H-2') -12
Tla, Mls, Ly 1, 2
B10K CBA/J H-1, -3, -7, -8, -9, 2/12 1/12 (11/12)$ (12/12)§ - +
(H-2k) -12
Mls, Ly 1, 2
BlO.BR CBA/H-T6 H-1, -3, -7, -8, -9, 0/5 0/5 5/5 5/5 - +
(H-2k) -12
Tla, Ly 2
AKR CBA/J H-1, -7, -12 0/6 1/6 6/6 ND - +
(H-2k
) Mls, Ly 1, Thy 1
C3H/He CBA/J H-3,-7,-9,43 1/12 0/12 8/12 ND - +
(H-2k) Mls
CBA/J C3H/He H-3, -7, -9, -13 0/6 1/6 6/6 6/6 - +
(H-2k) Mls
L29 B10 H-1,-3,-4,-9,-11, 1/12 1/12 4/6 6/6 - +
(H-2b ) -12,-13
L y 4, 7
CBA CBA/J Mls, Ly 1 0/6 0/6 2/6 2/6
H-T6 (H-2k)
B6 1310 H-9 1/6 0/6 3/6 2/6
(H-2b)
B109 13106 H- Y 0/6 0/6 (1/6)11 (0/6)11
(H-2°)100
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60 -
40 -
20 -
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Lethal GVHD in irradiated (750 rads) BIO.BR mice given unfractionated CBA/J marrow
cells. The data show cumulative mortality after injection of untreated syngeneic marrow cells
(B10.BR BM), anti-Thy 1.2-serum-treated CBA/J marrow cells (CBA a8 BM), untreated CBA/J
marrow cells (CBA BM) or CBA/J marrow cells supplemented with 106 or 107 peripheral
lymphocytes (PL) from pooled spleen and LN cells of normal CBA/J mice. Data from a single
experiment involving six mice per group.
TABLE II
Identity ofAnti-SRC PFC in BIO.BR --+ CBA/J and CBA/J --. BIO.BR Chimeras Reconstituted with
Anti-Thy 1.2-Serum-Treated Marrow Cells 3mo Previously
1693
" IgG PFC were enhanced with a rabbit anti-mouse Ig antiserum and Igb PFCwere enhanced with an
anti-Igb allotype antiserum as described in Materials and Methods.
# Geometric mean; number in parenthesis refers to value by which mean is multiplied or divided to give
upper andlower limits, respectively, of SE.
roughly comparable to the responses of syngeneic chimeras or nonirradiated mice.
Since BlO.BR and CBA/J have different Ig allotypes (Igb and Iga, respectively),
development of anti-SRC PFC with an anti-Igb anti-allotype serum enabled the
identity of the PFC to be determined. As shown in Table II, this antiserum developed
PFC from B10.BR mice but not from CBA/J mice. In the case of the B10.BR --~'
CBA/J combination, it is evident that the numbers of PFC enhanced by the anti-Igb
serum were as high (or higher) as in syngeneic BIO.BR --+ BlO.BR chimeras or in
normal B10.BR mice. Thus, the vast majority of the PFC were of donor origin. This
also appeared to be the case with CBA--* BIO.BR chimeras sincethese mice contained
only small numbers ofIgb PFC.
Mice given 0.1 ml of 25%
SRC intraperitoneally
Mice
per
group
Anti-SRC PFC/spleen at 7 days*
Igm IgG Igb Igb/IgG
Normal CBA/J 2 9,350 (2.03)$ 67,490 (1 .12) 0 0.00
Normal B10.BR 3 53,910 (1.30) 28,680 (1.22) 15,950 (1.32) 0.57
B10.BR CBA/J 3 43,510 (1 .11) 72,880 (1.22) 46,720 (1 .27) 0.66
CBA/J-~ CBA/J 3 10,260 (1 .09) 86,360 (1.29) 0 0.00
CBA/J B10.BR 3 43,520 (1 .27) 55,790 (1.26) 1,710 (2.62) 0.07
B10.BR-~ B10.BR 2 37,040 (1 .32) 28,980 (1.21) 13,420 (1 .12) 0.471694
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Discussion
The present data show that in two situations (B lO.BR --* CBA/J and vice versa),
transplantation of untreated MHC-identical marrow cells into heavily irradiated
allogeneic mice caused a high incidence of lethal chronic GVHD, i.e. mortality
occurring between days 20-80 post-transfer. GVHD was not observed when the
marrow cells were treated with anti-Thy 1.2 serum and complement before injection.
A priori, the protective effect of anti-Thy 1 .2 serum might have reflected activity
against (a) T-cell precursors, (b) mature T cells, or (c) both. The first possibility is
considered most unlikely because, in contrast to antisera raised in rabbits against
mouse brain, there is no evidence that anti-Thy 1 .2 serum prepared in mice has
specificity for pre-T cells (26) . The fact that GVHD was restored by the addition of
even small numbers of purified LN T cells, but not by adding Thy 1.2-negative cells,
strongly implies that mature T cells in marrow were the sole target of the antiserum.
Although marrow cells alone caused mortality in only two situations, it should be
emphasized that 100% mortality occurred in six other combinations when spleen and
LN cells were added to the marrow inoculum. Before discussing possible reasons for
the differing effects of untreated marrow cells, it is first necessary to consider the
nature of the antigenic determinants which led to GVHD with spleen and LN cells.
Although the precise identity of the non-MHC antigens evoking GVHD was not
established, it seems almost certain that minor H determinants were responsible.
Thus, it is evident from Table I that GVHD occurred only with differences at three
or more minor H loci. By themselves, Mls determinants did not appear to be involved
since GVHD was observed with two Mls-identical combinations (B10.BR -+ CBA/
H-T6 and 129/J --~ B10) . Moreover, Mls-incompatibility with identity at minor H
loci (CBA/H-T6 CBA/J) gave only minimal evidence of GVHD. Similarly, TLa
and Ly antigens were of no apparent importance since GVHD occurred with a
TLa-, Ly-identical combination (CBA/J -* C3H/HeJ) .2 However, the data do not
exclude the possibility that responses to these antigens or Mls determinants can
potentiate reactivity to minor H antigens. Establishing the precise identity of the
determinants evoking lethal GVHD will require further work. Double congenic
resistant strains differing only at defined minor H loci (29) would be required for this
purpose.
Since T cells comprise only a minority population (-2%) of mouse marrow cells
(30), it is perhaps not surprising that lethal GVHD caused by untreated marrow cells
alone was the exception rather than the rule. The degree of antigenic disparity
between donor and recipient probably contributed to the variable effects of marrow
cells per se. Strain variation in the proportion of T cells in marrow is another
possibility; although this notion has not been tested it is of interest that certain rat
strains show marked differences in numbers of T cells in marrow (31) . A third
possibility is that Ir genes contributed to the incidence of GVHD ; here it is of interest
that Ir genes control skin graft rejection (32), T-cell-mediated lympholysis (33, 34)
and antibody production (35) to certain minor H determinants. Finally, strain
variation in susceptibility to irradiation might have been involved. This was probably
z Qa determinahts (which map between the H-2D and Tla loci) deserve consideration since these
determinants evoke T-cell-mediated lympholysis (27, 28 and L. Flaherty, personal communication). Since
CBA/J mice express the nonstimulating (b) Qa alleles, the GVHD seen in this strain presumably did not
involve responses to Qa determinants.R. KORNGOLD AND J. SPRENT
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not an important factor in the present experiments since in several situations the
recipients were ofthe samestrain (CBA/J). However, recently it has become apparent
that the constitution ofthe host is indeed important since it has proved much more
difficult to induce GVHD in heterozygous mice than in homozygous mice. Thus,
whereas even small doses ofB1O.BRT cells killed CBA/J mice (Table I), evenmassive
doses (>10) of (BlO.BR X B10)F, T cells failed to kill MHC-compatible irradiated
(B6 X CBA)Fj mice in some experiments (data not shown).
It is clearly tempting to equate the GVHD seen in the present experiments with the
syndrome ofsecondary disease occurring after marrow transplantation in man. Does
it follow therefore that GVHD in man would be abolished by removing T cells from
themarrow inoculum? Although thisis an obvious predictionit hasto be remembered
that studies with healthy inbred mice are far removed from the clinical situation
where the transplant recipient is generally in poor condition. Moreover, the fact that
the recipient is frequentlypresensitizedas the result ofpriorblood transfusions implies
that a reciprocal HVG reaction is often involved. Finally, GVHD in man differs in
certain respects from that seen in mice; for example, skin lesions are rare in mice.
Despite these reservations, the present findings would seem to provide strong
support for the rationale for using T-cell-depleted populations as a source of hemo-
poietic stem cells in man, particularly because human marrow cells contain a much
higher proportion ofT cells (up to 30% [36]) than mouse marrow. Until specific anti-
T-cell reagents are available in man, fetal liver cells might represent the best
alternative (3, 37). However, although fetal liver cells often give good results, GVHD
still occurs on occasions. While in some cases this might reflect contamination with
small numbers of post-thymic T cells, an obvious complication with fetal liver
transplantsis that theHLA haplotype ofthe donor isusually unknown. In this respect,
an intriguing alternativeexplanation is provided by therecent findingsofZinkernagel
et al. (38, 39). These workers have shown that, even with T-cell-depleted marrow
cells, allogeneic radiation chimeras in mice usually die after 2-3 mo unless the donor
andhost share I-region H-2 determinants (identity at the H-2complexis not necessary
since a X b -)- a X c chimeras show good survival). In essence this study shows that
functional T cells develop only in situations where the hemopoietic stem cells share
H-2 determinants withthe thymus responsible forT-cell differentiation. Without such
sharing, the chimeras remain immunoincompetent and most eventually develop the
type of runt disease (closely resembling secondary disease) seen in other T-cell-
deficient states, e.g. in neonatally thymectomized mice. Two key predictions arise
from these findings. First, fetal liver cell transplantation in man should fail on a long-
term basis unless the donor and host share at least one HLA-D allele (the presumed
counterpart of the mouse I region). Second, transplantation with HLA-D-disparate
fetal liver should succeed if the thymus ofthe donor is also transplanted.
Summary
In two situations, transfer of normal unsensitized bone marrow cells into heavily
irradiated H-2-identical allogeneic mice caused a high incidence of lethal chronic
graft-versus-host disease (GVHD), i.e. mortality occurring between days 20 and 80
3 Whether the runt disease seen in bone marrow chimeras raised across complete H-2 barriers is indeed
the same as that found after neonatal thymectomy has yet to be proved. Nevertheless, it is striking that in
both situations runt disease fails to develop in a germ-free environment (2, 40).1696
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postirradiation. Minor histocompatibility determinants appeared to be the main
target for eliciting GVHD. Removing mature T cells from the marrow with anti-Thy
1 .2 serum and complement before injection prevented GVHD. On the basis of adding
purified T cells to T-cell-depleted marrow cells, it was concluded that contamination
of the marrow with as few as 0.3% T cells was sufficient to cause a high incidence of
lethal GVHD in certain situations. No GVHD was found with the injection of non-T
cells (Thy 1 .2-negative cells) or with tolerant T cells. Irradiated recipients of T-cell-
depleted marrow cells remained in good health for prolonged periods. These mice
showed extensive chimerism with respect to the donor marrow, normal numbers of T
and B cells and were immunocompetent.
The data provide no support for the view that chronic GVHD developing after
bone marrow transplantation in man is the result of an attack by the progeny of the
donor stem cells. The results imply that mature T cells contaminating marrow inocula
are probably the main cause of GVHD seen in the clinical situation.
We wish to thank Doctors W. L. Elkins, D. Gasser, T. J. McKearn, and P. C. Nowell for
reading the manuscript.
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